🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🎯 Our epigenomic controllers are designed with unmatched specificity. Each DNA-binding domain targets a single epigenomic zipcode or EpiZip, ensuring precise gene regulation. Learn more about the benefits of #EpigenomicControllers here: bit.ly/3xiJzZo

On #WorldCancerResearchDay, we join others in raising awareness of the ongoing urgent need for research to improve outcomes for patients living with #cancer & provide hope to families. See how you can support: bit.ly/48onmH2 WCRD

#Omegan Kathleen Davenport will be participating in a panel about commercial and product strategy considerations in early R&D at the New Product Planning Summit by Fierce Life Sciences Events! Watch her panel session here: bit.ly/3ZtQDxY

#HepatocellularCarcinoma (HCC) is the most common type of adult primary #LiverCancer & incidence is on the rise. This #LiverCancerAwarenessMonth, we support those affected and advocate for further research. Learn more about how you can get involved: bit.ly/3V1r3LX

The OMEGA platform has the potential to target nearly any human gene, even those once considered undruggable. Our recent publication in Nature Communications showcases this potential, paving the way for transformative treatments. Read more here: bit.ly/3ZtPypU

We’re looking forward to presenting at these scientific conferences: 🎤 Society for Immunotherapy of Cancer 39th Annual Meeting – 11/9 🎤 12th International #mRNAHealthConference – 11/12 🎤 AASLD’s 75th Annual Meeting – 11/17 Details here: bit.ly/3U4zsPR #SITC2024 International mRNA Health Conference #TLM24

#DYK that by 2030, 1 in 2 U.S. adults will live with #obesity? Currently available treatments are focused on managing symptoms, which is why we’re exploring the potential to manage obesity through #PrecisionEpigenomicControl with Novo Nordisk. More here: bit.ly/4cgF53K

🎉 #Omegans took a well-deserved break from our busy days to connect, celebrate achievements, and embrace the spirit of unity at our annual Fall get-together. Cheers to teamwork and the values that keep us strong! #OmegaValues

Our goal was to create a platform that can precisely target and control gene expression, and we did just that. The OMEGA platform has the potential to address a wide range of diseases, including some that currently have no disease-modifying treatments: bit.ly/3XMBdCx

Our CEO, Mahesh Karande, discusses key disruptors in the pharma industry in the latest issue of The Medicine Maker. Read his thoughts about the groundbreaking rise of #mRNA as a therapeutic modality: bit.ly/4hequtx

What sets the OMEGA Platform apart? ✔️ #EpigenomicControllers, designed to be highly specific for target gene ✔️ Customizable delivery tailored for specific diseases ✔️ AI-driven approach enabling rapid design, development, & optimization Learn more: bit.ly/3zsae6I

Epigenetic modifications control DNA’s 3D structure without changing the genetic code. Our OMEGA platform uses this understanding to design therapeutic candidates that act pre-transcriptionally to regulate gene expression. Learn more about our science: bit.ly/4couGU9

At #SITC2024, we presented a poster highlighting that controlled epigenomic upregulation of CXCL9 & CXCL10 in #HepatocellularCarcinoma promotes T-cell recruitment. This exemplifies the versatile capabilities of the OMEGA platform. Learn more here: bit.ly/491M6FX

Today we announced our Third Quarter 2024 financial results, completion of our Phase 1 study and strategic updates. Learn more in our press release: bit.ly/3URA77S $OMGA

At the 12th International #mRNAHealthConference & @AASLDtweet’s The Liver Meeting®, we shared exciting preclinical data showcasing durable upregulation of #GeneExpression by our #EpigenomicControllers. Read how this work advances our mission here: bit.ly/4fAkPMY

At Omega, we’re grateful for our dedicated team working to advance innovative #EpigenomicControllers for patients in need. We deeply appreciate the passion of our #Omegans and the values that drive us. #OmegaValues

Currently available #obesity treatments focus on appetite management and may not be effective for every patient. At Omega, we’re partnering with Novo Nordisk to potentially reimagine obesity management using an #EpigenomicController. Read more here: bit.ly/4cgF53K

#ICYMI, we shared a poster at AASLD’ #TLM24 showcasing durable upregulation of HNF4α using an #EpigenomicController. This represents a potentially novel therapeutic strategy for the treatment of fibrotic liver disease. View the poster here: bit.ly/4eVuSeF

Wishing all our #Omegans and their families a healthy, joyful, and peaceful holiday season! Thank you for your hard work, dedication, and passion throughout the year.

❓ What makes our approach different? #EpigenomicControllers are programmed to target unique sequences within the genome with high specificity to tune gene expression for a tailored duration. Learn more about the potential impact of our approach: bit.ly/3xiJzZo